AC699
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AC699, covering 2025-09-30 to 2025-09-30. Get the full timeline:
Most recent: Clinical Trial Update: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer [Phase 1]